BioDelivery Sciences International
Specialty pharmaceutical company focusing on pain management and addiction medicine.
Launch date
Employees
Market cap
€525m
Enterprise valuation
€474m (Public information from Sep 2024)
Share price
$5.59 BDSI
Raleigh North Carolina (HQ)
Financials
Estimates*
| USD | 2019 | 2020 | 2021 | 2023 |
|---|---|---|---|---|
| Revenues | 111m | 156m | 167m | 252m |
| % growth | - | 40 % | 7 % | - |
| EBITDA | 12.6m | 40.5m | 44.5m | - |
| % EBITDA margin | 11 % | 26 % | 27 % | - |
| Profit | (15.3m) | 25.7m | 84.9m | - |
| % profit margin | (14 %) | 16 % | 51 % | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | IPO | |
| N/A | $40.0m | Post IPO Equity | |
| N/A | $20.0m | Debt | |
| N/A | $60.0m | Post IPO Equity | |
| N/A | $20.7m | Post IPO Debt | |
N/A | Post IPO Debt | ||
$50.0m | Post IPO Equity | ||
| N/A | $60.0m | Post IPO Debt | |
* | N/A | Acquisition | |
| Total Funding | - | ||
Recent News about BioDelivery Sciences International
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.